Rare variants and cardiovascular disease

Insights

Genetic studies reveal common variants explain little cardiovascular disease (CVD) risk. Rare variants in monogenic CVDs and genome-wide association studies (GWASs) are converging to uncover key biological mechanisms.

Area of Science:

  • Genetics
  • Cardiology
  • Genomics

Background:

  • Cardiovascular disease (CVD) is a major cause of death and illness globally.
  • Genome-wide association studies (GWASs) have identified common genetic variants associated with CVD and its risk factors, but explain little phenotypic variance.
  • Studies of monogenic cardiovascular diseases (CVDs) have identified genes crucial to disease etiology.

Purpose of the Study:

  • To review how findings from rare variant studies in monogenic CVDs and GWASs of common variants are converging.
  • To provide further insight into the biological mechanisms underlying cardiovascular disease.

Main Methods:

  • Review of existing literature on genetic studies of cardiovascular disease.
  • Analysis of findings from genome-wide association studies (GWASs) of common variants.
  • Examination of studies on rare variants in monogenic cardiovascular diseases.

Main Results:

  • Common variants identified through GWASs explain a small proportion of CVD phenotypic variance.
  • Rare variants are hypothesized to contribute to the missing heritability in CVD.
  • Studies of monogenic CVDs have successfully identified key genes involved in disease etiology.

Conclusions:

  • Converging evidence from rare variant and common variant studies offers deeper insights into CVD mechanisms.
  • Understanding both common and rare genetic variations is crucial for elucidating cardiovascular disease etiology.
  • Future research on rare variants in cardiovascular traits is warranted.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
11.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K